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Chimeric antigen receptors (CARs) can effectively redirect cytotoxic T cells toward highly expressed 
surface antigens on tumor cells. The low expression of several tumor-associated antigens (TAA) on 
normal tissues, however, hinders their safe targeting by CAR T cells due to on-target/off-tumor 
effects. Using the Multiple Myeloma (MM)-associated CD38 antigen as a model-system, we here 
present a rational approach for effective and tumor-selective targeting of such TAAs. Using the “light 
chain exchange” technology, we combined the heavy chains of two high-affinity CD38 antibodies 
with 176 germline light chains and generated ~124 new antibodies with 10 to >1000-fold lower 
affinities to CD38. After categorizing them in three distinct affinity classes, we incorporated the 
single-chain variable fragments of eight antibodies from each class into new CARs. T cells carrying 
these CD38-CARs were extensively evaluated for their on-tumor/off-tumor cytotoxicity as well as 
CD38-dependent proliferation and cytokine production. We identified CD38-CAR T cells of ~1000- 
fold reduced affinity which optimally proliferated, produced Th1 like cytokines and effectively lysed 
CD38++ MM cells but spared CD38+ healthy hematopoietic cells, in vitro and in vivo. Thus, this 
systematic approach is highly suitable for the generation of optimal CARs for effective and selective 







Cytotoxic T cells endowed with chimeric antigen receptors (CARs) against surface antigens on tumor 
cells can induce powerful anti-tumor effects in experimental models and long term remissions in 
clinical trials. Specifically CAR T cells targeting CD19, an antigen present in B-cell leukemias and 
lymphomas, have shown impressive clinical results.1–5 Hence, CAR T cells are currently considered 
highly appealing tools for cancer immunotherapy. Ideally the target molecule for CAR T cell therapy 
should be specifically expressed on tumor cells. Nonetheless, several years of research have identified 
only a few true tumor-specific surface antigens. Currently most tumor-associated target antigens 
(TAA) are expressed, albeit at low-to-intermediate levels, also on one or more normal tissues, such as 
epidermal growth factor receptors (EGFR and ErbB2/Her2), prostate specific membrane antigen 
(PSMA) or Carcinoembryonic antigen (CEA).6,7 Targeting such antigens with CAR T cells raises 
safety concerns, due to on-target off-tumor toxicities with unpredictable severity. The application of 
carbonic anhydrase IX–specific CAR T cells in renal cell cancer resulted in liver toxicities8 and CEA-
specific CAR T cells in colon cancer patients induced severe colitis.9 Additionally, a high antigen 
load, on tumor and healthy tissues can elicit a significant cytokine response when targeted with highly 
reactive T cells.3,10,11 Targeting HER2 with CAR T cells caused a fatal cytokine release syndrome 
(CRS), due to the recognition of low levels of HER2 expressed on the cells of lung epithelium.12  
 
In a recent preclinical study we have shown that CD38 is a useful target antigen for the treatment of 
multiple myeloma (MM) and that high affinity CD38-CAR T cells have significant anti-MM function 
in vitro and in vivo.13 Although CD38 is expressed at very high levels on all MM cells, it is also 
present at intermediate levels on several hematopoietic cells, including NK cells, monocytes and a 
fraction of T cells. As expected, with high affinity CD38-CAR T cells we not only observed strong 
anti-MM effects, but also noted on-target off-tumor effects against normal hematopoietic cells. 
 
Optimization of the design of the extracellular recognition domain of CARs has been proposed, among 
others, as an approach in order to enhance the capacity of CAR T cells to discriminate between tumors 




have been observed when using single chain variable regions (scFv) of existing low(er) affinity 
antibodies.14–16 Thus, actively decreasing and optimizing the affinity of existing antibodies could allow 
for minimizing the off-tumor CAR responses, which in fact has been achieved by the introduction of 
mutations or the replacement of human with murine residues in the scFv domain.16–19 Nonetheless, a 
convenient approach that can be utilized to de novo generation of a large panel of candidate scFvs and 
methodically selection of those CARs with an optimal target affinity is still lacking.  
 
We here describe a rational and feasible strategy, using CD38 as a model-antigen, for 
tumor-associated but not entirely tumor-specific antigens. To generate new antibodies binding the 
same epitope with a broad range of different affinities, we used the light chain exchange technology.20–
23 Combining the heavy chains of two high-affinity CD38 antibodies with 176 germline light chains 
allowed the generation of more than a hundred new CD38 antibodies with 10-1000 fold lower 
affinities to CD38. The panel of candidate scFvs was narrowed down using rational selection criteria 
based on the desired immunotherapeutic properties of CAR T cells. Systematic in vitro and in vivo 
analysis of the newly generated CARs revealed that CAR T cells bearing scFvs derived from ±1000-
fold lower affinity antibody were tumor selective killers with strong lysis of CD38++ MM cells and 











Antibody production by Light chain exchange 
Variable heavy- and light chain coding regions were cloned in the pcDNA3.3 (Invitrogen) based 
vectors p33G1f and p33Kappa respectively. All 352 antibodies were produced under serum-free 
conditions by individually co-transfecting 2 heavy chains (024 and 028) and 176 germline light chain 
expression vectors in HEK-293F cells, using 293fectin (Invitrogen), as previously described.24 A 
simple, robust and highly efficient transient expression system for producing antibodies.24 Cell-free 
supernatants were harvested and antibody concentrations were determined by Octet IgG quantification 
(Forté Bio). 
 
Bio-layer interferometry   
Affinities were measured and ranked using biolayer interferometry on a Octet HTX instrument 
(ForteBio). Anti-Human IgG Fc Capture biosensors (ForteBio) were loaded for 1000 s with hIgG1 
containing different heavy and light chain combinations directed against CD38. After a baseline (100 
s) the association (1000 s) and dissociation (1000 s) of the extracellular domain of N-terminally His-
tagged CD38 (His-CD38,100 nM) in Sample Diluent (ForteBio) was determined. For calculations, the 
theoretical molecular mass of His-CD38 based on the amino acid sequence was used, i.e. 30.5 kDa. 
Experiments were carried out while shaking at 1000 rpm and at 30 °C. Data was analyzed with Data 
Analysis software v8.0 (ForteBio), using the 1:1 model and a local full fit with 1000 s association time 
and 250 s dissociation time. Data traces were corrected by subtraction of the average of 4 reference 
biosensors loaded with IgG1-3003-028 WT and incubated with Sample Diluent only. The Y-axis was 
aligned to the last 5 s of the baseline, and interstep correction as well as Savitzky-Golay filtering was 
applied.  
 
Antibody Binding assay 
Homogenous binding assays for human CD38 specific antibodies were performed in 1536 well 




CHO cells transiently expressing human CD38, CHO wt background control and streptavidin beads 
coated with purified biotinylated his-tagged human CD38 was detected with a secondary polyclonal 
goat IgG anti-Human IgG (Fc) - Alexa Fluor 647 conjugate (Jackson ImmunoResearch). In parallel, 
the binding of IgG1 antibodies to streptavidin beads coated with purified biotinylated his-tagged 
human CD38 was also assessed using a monovalent secondary goat Fab anti-Human IgG, (H+L) - 
DyLight 649 conjugate (Jackson ImmunoResearch). IgG1 samples were normalized and diluted in 
Freestyle 293 expression medium (Gibco). Two microliter of diluted sample was added to 5 microliter 
cell or bead suspensions containing secondary conjugates at 200 ng/mL IgG conjugate or 300 ng/mL 
Fab conjugate, respectively. Cell suspensions were prepared in FMAT buffer (PBS, 0.1% BSA and 
0.02% Sodium Azide) + 0.075% Pluronic F-68. Bead suspensions were prepared in HBB (10-mM 
HEPES (pH 7.4), 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 0.5% BSA and 0.01% 
Sodium Azide + 0.075% Pluronic F-68). After 8 hours incubation at RT in the dark, fluorescence 
signals were recorded using the Applied Biosystems 8200 Cellular Detection System (ThermoFisher 
Scientific) with a 50 counts cut-off value applied. Obtained total fluorescence intensity data was 
processed and visualized using ActivityBase software (IDBS). 
 
Introduction of CD38-specific scFvs in CAR constructs   
The selected variable light and heavy chains were amplified using PCR with primers (supplemental 
table S3) containing homology arms and Gibson assembly (NEB) was used to combine both chains 
linked with a G4S linker. The generated scFvs were cloned into SFG retroviral vector, followed by a 
CD8a transmembrane domain and the 4-1BB and CD3ζ signaling domains as described in Zhao et al.25 
The CAR constructs were linked by a 2A sequence to a truncated NGFR or dsRed sequence.26 
 
Generation of retroviral particles and transduction of T cells  
Phoenix-Ampho packaging cells were transfected with the CAR constructs, gag-pol (pHIT60), and 
envelope (pCOLT-GALV) vectors (Roche). Two and three days after transfection, cell free 




Peripheral Blood Mononuclear cells (PBMCs) from healthy donors were stimulated with lectin-like 
phytohemagglutinin (PHA-L) in RPMI-1640 + 10% FBS. After 48 hours, cells were retrovirally 
transduced using spinoculation on retronectin (Takara) coated plates in the presence of Polybrene .A 
second transduction was done after 16 hours. 72 hours post-transduction LNGFR or dsRed and CD38 
expression was determined by flow cytometry. T cells were expanded using culture medium (RPMI-
1640, 10% human serum, antibiotics), and 50 IU/ml rhIL-2 (Proleukin®, Novartis). One week after, 
CAR-transduced T cells were either stimulated with irradiated (5 Gy) UM9 cells (E:T ratio 1:3) or 
tested functionally.  
 
Primary cells from MM patients and healthy individuals.  
Bone marrow mononuclear cells (BMMC) containing 5-40% malignant plasma cells were isolated 
from bone marrow aspirates of MM patients through Ficoll-Paque density centrifugation and either 
used directly or cryopreserved in liquid nitrogen until use. PBMCs/MNCs were isolated from Buffy 
coats of healthy blood-bank donors by Ficoll-Paque density centrifugation. All primary samples were 
obtained after informed consent and approval by the institutional medical ethical committee.   
 
Cell lines  
Unmodified or luciferase (Luc-GFP)-transduced human MM cell lines, UM9 and RPMI8226 were 
cultured in RPMI-1640 (Invitrogen) + 10% FBS (Invitrogen) + antibiotics (penicillin;10.000 U/ml, 
streptomycin; 10,000 µg/ml) as described.13  
 
Cloning, expression and purification of CD38 extracellular domain (sCD38) 
A synthetic DNA construct encoding the Honeybee Melittin signal sequence (HMSS) fused to a 
fragment of the extracellular CD38 domain encoding residues 43-400 was purchased (GeneArt). The 
HMSS-CD38 DNA was cloned into the pFastBacNKI-LIC-3C-his vector27 to get pFastBACNKI-
HMSS-CD38-3C-his (C-terminal 6xhis-tag). Bacmid DNA and virus were essentially prepared 
according to the Bac-to-Bac manual (Thermo Fisher Scientific). Briefly, the pFastBACNKI-HMSS-




insect cells were transfected with bacmid DNA and virus was harvested. Virus was amplified and used 
to infect sf9 cells for protein expression. Secreted proteins were harvested and concentrated in using a 
Fresenius Polysulfone F40S dialyzer (Fresenius Medical Care). CD38 was purified on a HiTrap Ni2+ 
column and eluted with 200 mM imidazol in 25 mM NaCl pH 8.0, 200 mM NaCl. CD38 was further 
purified by size exclusion chromatography on a S200 16/60 Superdex column (GE Healthcare) 
equilibrated with 25 mM NaCl pH 8.0, 200 mM NaCl buffer. The protein eluted in a single peak and 
fractions containing the protein were pooled and concentrated. 
 
Flow cytometry  
Flow cytometry assays were performed on FACS CantoII or LSR Fortessa (BD). Different cell subsets 
in T cells, PBMC or in BM-MNC in were determined using fluorescein conjugated antibodies specific 
for human CD3, CD4, CCR7, CD8, CD14, CD19, CD38, CD45, CD45RA, CD56, CD62L, and 
CD138 (BD Bioscience). Viable cells were determined with live/dead cell marker (LIVE/DEAD® 
Fixable Near-IR; Life Technologies L10119).  
 
Detection of CAR expression 
The sCD38 protein was used in flow cytometry experiments to determine the cell surface expression 
levels of high affinity CARs and to correlate to this with the expression of LNGFR, measured with an 
either PE or APC conjugated antibody to LNGFR (CD271) (Biolegend).An almost perfect correlation 
was found between the sCD38-aided measurement of CAR expression and the NGFR expression 
(supplemental Fig. S2). After this validation, transduction efficiency and associated CAR expression 
of other CAR transduced cells was done by NGFR measurements since sCD38 did not bind to CARs 
with low affinity. We confirmed a comparable NGFR expression in all tested CAR T cells, the 
expression of the selected CARs are depicted in supplemental Fig. S3. 
 
Flow cytometry-based cytotoxicity assay  
Seven to ten days after transduction serial dilutions of CAR T cells were incubated with Violet tracer 




Fluorospheres (Beckman 7547053) cells were harvested and stained for different CD markers (see 
above). Viable cells were then quantitatively analyzed through Flow-Count-equalized measurements. 
Percentage cell lysis was calculated as followed and only if the analyzed target cell population 
contained >500 viable cells in the untreated samples. % lysis cells = 1 − (absolute number of viable 
target cells in treated wells / absolute number of viable target cells in untreated wells) × 100%. 
 
Bioluminescent Imaging based cytotoxicity assay  
To determine the lysis of Luc-GFP-transduced human malignant cell lines by CD38-CAR T cells 
seven to ten days after transduction., Serial dilutions of mock or CD38-CAR T cells were co-incubated 
with the malignant cell lines. The luciferase signal produced by surviving malignant cells was 
determined after 16-24 hours with a GloMax® 96 Microplate Luminometer (Promega) within 15 
minutes after the addition of 125 μg/mL beetle luciferin (Promega). % lysis cells = 1 − (BLI signal in 
treated wells / BLI signal in untreated wells) × 100%. 
 
Cytokine measurement  
To determine the broad array of cytokines produced by CAR T cells, we used the Cytokine Bead 
Array (CBA) Human Th1/Th2 cytokine kit (BD) according to manufacturer protocol. In brief, CAR T 
cells at 7 days post transduction were stimulated with either UM9 or U266 cells for 24 hours. Cell free 
supernatants were harvested and incubated with a mixture of capture beads (IL-2, IL-4, IL-5, IL-10, 
TNF and IFN-γ), PE-detection reagent for 3 hours. Beads were washed and analyzed by a standardized 
flow cytometry assay. 
 
Hematopoietic progenitor cell growth inhibition assay 
A total of 1000 CD34+ sorted BM cells were mixed with effector CART cells at a CART:BM cell ratio 
of 1:1 in 0.2 mL of RPMI culture medium. After culturing for 4 hours in this small volume, the cells 
were resuspended to a final volume of 2 mL with semisolid Methocult (Stem cell technologies, 




colony-forming unit-granulocytes (CFU-G), and CFU-monocytes (CFU-M), were scored under a 
microscope. 
 
In vivo xenograft studies 
RAG2-/-γc-/- mice used in this study were originally obtained from the Amsterdam Medical Center 
(AMC, Amsterdam, the Netherlands) and were bred and maintained at the Amsterdam Animal 
Research Center. All animal experiments were approved by local ethical committee for animal 
experimentation and were in compliance with the Dutch Animal Experimentation Act. 
We used an in vivo model, in which a humanized bone marrow-like environment is created in mice29to 
allow the growth of human MM tumors or normal CD34+ cells in their natural niche. Briefly, hybrid 
scaffolds consisting of three 2- to 3-mm3 triphasic calcium phosphate particles were coated in vitro 
with human bone marrow mesenchymal stromal cells (BM-MSC)(2×105 cells/scaffold). The scaffolds 
were implanted subcutaneously into the mice29. Eight to twelve weeks after implantation, mice were 
i.v. injected with luciferase-transduced UM9 MM cells to monitor the anti-tumor effects of CAR T 
cells. In a separate experiment, fluorescent (FarRed) labeled CD34+ cells were injected into the 
scaffold to monitor the on-target off-tumor effect of CAR T cells. After one week, when the tumors or 
CD34+ cells became detectable by bioluminescence imaging (BLI) or Fluorescence life imaging (FLI), 
respectively, mice were divided in equal groups; CD38-CAR- or mock-transduced T cells (5×106 
cells/mice) were injected by tail i.v. injections. Tumor growth or CD34+ cell persistence was 
monitored by weekly BLI measurements. Postmortem bone marrow, spleen and scaffolds were 
harvested from each mouse, dissociated (spleen and scaffolds), filtered through a 70 µm filter and 
single cell suspensions were counted, stained and measured by flow cytometry.  
 
Statistical methods. Statistical analyses were performed using Graphpad Prism software 6. In 
analyses where multiple groups were compared, either a parametric ANOVA or nonparametric 
Kruskal-Wallis test were used with subsequent multiple comparison. A p value <0.05 was considered 






Generation of lower affinity CD38 antibodies by light chain exchange.  
To generate lower affinity CD38 antibodies we applied the light chain exchange technology, in which 
we combined the heavy chains of high affinity antibodies 028 and 024 (described in patents 
WO2011154453 and WO2006099875) with 176 random germ line light chains, schematically 
depicted in figure 1A. One of these two antibodies, 028, was previously used to generate high affinity 
CD38-CAR T cells.13 Based on previous studies, pairing of heavy chains with numerous different light 
chains (light chain exchange or light chain shuffling) results in the alteration of binding affinity but not 
epitope specificity of the antibody.21,22,30–32 Among 352 combinations, 262 antibodies were properly 
expressed in sufficient quantities, and 124 of them showed binding towards CD38+ transfected, but not 
CD38- WT CHO cells (Fig. 1B first and fourth panel) indicating their CD38 specificity. 69 of these 
124 antibodies also showed binding to recombinant CD38 coated beads. While 23 of these 69 
antibodies showed bivalent binding (IgG), the remaining 46 displayed bi- and monovalent (Fab 
fragment) binding (quantified EC50 values for each detection method are depicted in Fig. 1C). 
Antibodies with the strongest binding capacity also displayed a detectable biolayer interferometry 
signal on an Octet HTX instrument, whereby the on-rate (kon), off-rate (koff) and affinity constant (KD) 
(Fig. 1D and E) could be determined. As illustrated in figure 1E left panel, the KD values of those 
antibodies were 10 to 1000 times lower than the KD of the original antibody 028. Based on these data 
we classified all functional antibodies into three classes: Class A represented antibodies with a similar 
binding profile to CD38 as the parental (wildtype) antibodies but with ±10-1000 x lower affinity. 
Class B antibodies had no detectable affinity by biolayer interferometry but binding to CD38-positive 
cells/beads, (thus >1000x lower affinity to the original antibody), while the class C antibodies showed 
solely binding to CD38 positive cells, thus with an affinity even lower than the category B. Sequence 
similarities and differences in complementary determining regions (CDRs) of these antibodies are 
illustrated in supplemental table S1. We selected 8 antibodies from each class and generated 24 
different CARs using their scFvs. A selection of soluble scFvs were evaluated for unwanted, induced 




(supplemental Fig. S1). PBMC-derived T cells from a healthy donor were transduced with the selected 
24 newly generated CARs. 
 
Anti-Myeloma activity of CD38-CAR T cells with variable affinities. 
Since the anti-tumor function of CAR T cells is of primary importance, we first determined the lytic 
capacity of the newly generated CD38-CAR T cells against the CD38-positive MM cell line UM9. 
While CAR T cells generated from class C antibodies did not lyse the UM9 cells at all, T cells 
transduced with CARs from Class B and A antibodies were capable of lysing MM cells. As predicted, 
the highest affinity CARs (class A) were better in lysing tumor cells, compared to class B (Fig. 2). 
Interestingly, some T cells transduced with class A antibodies (CARAx T cells) lysed the UM9 cell 
line as effective as the CAR T cells which were generated from the original 028 antibody (CAR028 T 
cells) despite their much lower affinity for CD38. On the other hand, all CARs with the 024 variable 
heavy chain (VH) (CARs 5 - 8 in each class) elicited inferior tumor cytotoxicity compared to CARs 
generated using the VH of the 028 antibody (CARs 1 - 4 in each class). Based on these results, 2 of the 
best CARs from both class A and B were selected (CARA1, A4, B1 and B3) (Fig. 2 indicated with 
arrows), and were analyzed for their proliferative capacity cytokine production and on-target off-tumor 
cytotoxicity to gain more insight into their immunotherapeutic properties. 
 
Cytokine release of lower affinity CAR T cells  
The selected CAR T cells were first tested for their CD38-dependent cytokine production after 
stimulation with MM cell line UM9. All four CAR T cells, similar to the control high affinity CAR028 
T cells, produced IFN-γ, IL-2 and TNFα in the presence but not in the absence of CD38+ target (Fig. 
3A). Little or no IL-4, IL-5 or IL-10 (supplemental Fig. S4) were produced, thus indicating a typical 
Th1 cell phenotype. The level of cytokine production showed some association with the CAR affinity 
for CD38. Importantly however, the level of cytokine secretion by CARA1- and A4-transduced T cells 






Proliferation and expansion of lower affinity CAR T cells 
We have previously showed that high affinity CD38-CAR T cells display a slower growth rate in the 
first two weeks due to fratricide. After this period they readily expanded, but displayed no CD38 
expression on the cell surface. Therefore we also tested the CD38-dependent in vitro proliferative 
capacity and the immunophenotype of the four candidate CAR T cells after one week of transduction 
and after weekly stimulations with irradiated UM9 cells (Fig. 3 B and C indicated with arrows). The 
candidate CAR T cells displayed a similar or better growth rate compared to the control CAR028 T 
cells with the exception of CARA1 T cells. Furthermore the CARA4-, B3- and B1-T cells retained 
their CD38 expression, as opposed to CAR028 T and CARA1 T cells, (supplemental Fig. S3 right 
panel). Interestingly, lower affinity CAR T cells contained >50% central memory cells at the end of 
the production stage (1 week after transduction), similar to the mock control and in contrast to 
CAR028 T cells. As expected, however all cultures converted to predominantly effector memory (EM) 
cells after in vitro stimulation and expansion with tumor cells (Fig. 3C). 
 
T cells endowed with lower affinity CARs mediate no or minimal off-tumor effects  
Since our specific aim was to generate CAR T cells with minimal off-tumor on-target effects by 
affinity optimization, we finally determined the cytotoxic activity of the four selected CARs towards 
MM cells as well as normal healthy cells. Although CD38 can be expressed on several tissues, we 
studied hematopoietic cells as the prominent candidates of off-tumor effects because preliminary 
immunohistochemistry assays of several normal tissues revealed that the expression of CD38 was the 
highest in hematopoietic cells (data not shown). For a side-by-side comparison of the on-tumor and 
off-tumor effects, we used primary bone marrow mononuclear cells (BM-MNCs) from MM patients as 
target cells, in which CD38+ normal hematopoietic cells coexist with CD38++ primary MM cells. Thus, 
after incubation of CAR T cells with BM-MNC we determined the lysis of MM cells and normal 
hematopoietic cells in the same sample by quantitative flow cytometry. The CAR T cells lysed 
CD38++ MM cells in a roughly affinity-associated fashion ranging from 98% lysis for CARA1 to 68% 
lysis for the lowest affinity CARB3. (Fig. 4A top panel). Importantly, the lysis levels of CARA1 and 




The lysis of CD38+ fractions of normal B, T, NK cells and monocytes by CARA1, A4, B1 and B3 T 
cells comprised 84, 24, 23 and 6%, respectively, while the mock T cell mediated background lysis was 
7%. Thus except CARA1 T cells, all other candidates showed negligible or no off-target effects on 
CD38+ fractions of normal hematopoietic cells. When the hematopoietic cells were analyzed 
regardless of CD38 expression the total hematotoxicity of CARA1, A4, B1 and B3 T cells comprised 
only 20, 3, 20, 0%, respectively of which 11% was background, mock T cell mediated lysis. In 
contrast, the off-tumor effect of control CAR028 T cells was substantially higher (90% lysis of CD38+ 
fraction; 39% lysis regardless of CD38 expression) (Fig. 4 B, C, illustrative flow cytometry plots in 
4D). These data indicate that indeed the newly generated low affinity CAR T cells have minimal off-
tumor effects. 
 
Selection of the best lower affinity CD38-CAR T cells.  
Finally, to rationally select the most optimal CAR T cell, we summarized the in vitro data of the 
candidate CD38-CAR T cells, primarily according their anti-MM cytotoxicity and off-tumor 
hematopoietic cell toxicity, and secondarily according to cytokine production and proliferative 
capacity (supplemental table S2). Based on these criteria we excluded CARB3 T cells due to too low 
anti-tumor reactivity and CARA1 T cells due to too high off-tumor effects (Fig. 5). The remaining 
candidates were compared according to the secondary criteria. The CARA4 appeared the best 
performer since its proliferative capacity and especially the cytokine production was much better than 
that of CARB1. 
 
The in vivo anti-tumor effects of CARA4 T cells  
We then evaluated the in vivo anti-tumor and off-tumor effects of CARA4 T cells and compared these 
effects with those of CAR028 and mock T cells. To mimic the human MM microenvironment, we 
used the specific Rag2-/-γc-/- xenograft murine model, where the luciferase transduced tumor cells are 
grown in humanized BM like-niches generated by subcutaneous implantation of ceramic scaffolds 
coated with human bone marrow stromal cells (hu-BMSCs).29 As illustrated in figure 6A, in the 




curative, treatment of the tumor-bearing mice either with CAR028 or CARA4 T cells induced a 
significant and apparently similar anti-tumor effect (Fig. 6A, B). We did not encounter a tumor escape 
due to antigen-loss variants since post mortem analyses revealed that all remaining tumor cells in the 
mice were CD38+ (supplemental Fig. S6).  
 
The in vivo on target off-tumor effects of CARA4 T cells 
In the in vivo model we observed the maximum anti-tumor effects in the first three weeks (Fig. 6). To 
evaluate whether the CARA4 T cells or CAR028 T cells would induce any undesired on-target off-
tumor effects in this period, we  injected fluorescent (FarRed) labeled CD38+CD34+ normal 
hematopoietic progenitor cells in the humanized scaffolds and treated the mice with i.v. injected CAR 
T cells. The FLI signal from normal hematopoietic progenitors was followed during 3 weeks. Injection 
of CARA4 T, CAR028 T or mock T cells had no effect on the FLI signal (Fig. 7A). This observation 
was confirmed by CAR028 and CARA4 pre-treated CD34 cells, which could still form similar 
numbers of colonies in a colony forming assay (supplemental Fig. S7). Nonetheless, post-mortem 
analysis, after three weeks revealed in mice treated with CAR028 T cells significantly lower 
percentages (Fig. 7B) and total cell numbers (Fig. 7C) of CD38+ cells within the CD34+ fraction. 
Similar results were observed within the more differentiated CD34- fractions as compared to CARA4 
T cell treated animals (Fig. 7B and C).  
This indicated that CARA4 had no effect on CD34+ progenitor cells or more differentiated 
hematopoietic cells even if they expressed CD38. In contrast, treatment with CAR028 T cells did not 
hamper the total FLI signal, mediated toxicity against all CD38+ cells including the progenitor and 
differentiated cells. Since this could eventually result in defects in the differentiation of some lineages 






CAR T cells have produced remarkable clinical results when targeting CD19, a surface molecule 
present on B-cell malignancies.33 However, the broader application of CAR T cell therapy on the 
majority of cancers is limited by the simultaneous expression of TAAs - which are otherwise attractive 
CAR targets - on healthy tissues. Here, we propose a new feasible technique for the generation of a 
large panel of antibodies with different affinities. A systematic analysis and careful identification of 
suitable scFvs, enabled CARs that effectively target tumors with little or no off-tumor effect. We show 
that TAAs, such as CD38 for MM, can be selectively targeted by an scFv with an optimal affinity to 
the target antigen.  
 
Equipping CARs with scFvs of lower affinity has been shown to avert on-target off-tumor effects and 
create a tumor selective window for targeting TAA with CAR T cells.14,15 Tuning the affinity of 
existing antibodies by single amino acid substitutions in the scFv region16,18 can be a useful method to 
create a panel of alternative CAR constructs. However, the optimal affinity range appears to differ 
enormously when targeting different epitopes or target antigens. Chmielewski et al18 described 
affinities of 15-16 nM as optimal for tumor-selective ErbB2 targeting whereas Liu et al. determine an 
optimal antibody affinity of 1.1 nM for the same antigen. In our study, we exchanged the antibody 
light chain while keeping the heavy chain constant, which is suggested to modulate the affinity but not 
the epitope specificity of an antibody.30,31 In contrast to previous studies, in which a limited panel of 
no more than 8 new scFvs was tested,15,16,19,34 the light chain exchange technology allowed us to 
rapidly generate hundreds of new antibodies with a large range of affinities to the CD38 molecule. 
Thus, we were able to methodically identify the optimal candidate with the desired immunotherapeutic 
properties whereby a truly tumor-selective cytotoxic activity could be achieved. In fact our results as 
well as the results of others,14–16,34 indicate that such a systematic approach is necessary because, as 
mentioned above, there are yet no universal parameters, which could help to predict the optimal 
antibody/scFv affinity for each epitope and every target antigen. Interestingly, with this technique we 
could lower the highest antibody affinity of 1.8 nM more than a 1000-fold and still obtain CARs with 




affinity of the scFvs to the CD38 antigen, the affinities of the selected antibodies correlated well with 
the CAR activity. 
 
In order to select the optimal CAR construct we followed a logical approach in which we started with 
heavy chains of two high affinity antibodies (024 and 028) and extensively characterized the generated 
new antibodies for their affinity. We then categorized these antibodies into three “affinity groups” and 
selected 8 representative antibodies from each group, hereby pragmatically decreasing the pool to 24 
scFv candidates to construct new CARs. The resulting 24 CAR constructs were first screened 
according to their anti-tumor cytotoxicity, since this is the most crucial desirable immunotherapeutic 
function. This approach appeared highly convenient since we could readily eliminate all antibodies 
within the lowest affinity class. Furthermore, although the candidate antibodies did not show 
significant affinity differences, the CARs generated from the 024 heavy chain were in general inferior 
as compared to CARs generated from 028 heavy chain, indicating the importance to start with more 
than one heavy chain, whenever possible. Although some 024 CARs showed intermediate lysis of MM 
cells, we continued only with 028-antibody based CARs, as there were already excellent candidates 
within this category. We extensively evaluated 4 candidates from this group which elicited >50% anti-
tumor cytotoxicity in our in vitro assays. To select the most optimal CAR we thoroughly evaluated 
their several functional properties such as cytokine secretion, long-term antigen-specific proliferation, 
immunophenotype, but more importantly their on-target and off-tumor cytotoxicity against primary 
human samples. We finally selected the CARA4 as the most optimal CAR  T cells transduced with 
this CAR elicited similar anti-MM cytotoxic response like the original CAR028, but without having 
significant off-tumor toxicity on primary hematopoietic cells. Furthermore their long-term 
proliferation capacity was also similar to the original high affinity CAR028 T cells and they 
maintained Th1 cytokine production, which was even better than the other potential candidate 
CARB1.  
To our knowledge this is the first study where CARs bearing scFvs with different antigen affinities are 
thoroughly tested in vitro and scored for all the above-mentioned properties, which define the 




delay MM tumor growth in a manner similar high affinity CD38-CAR028 T cells was also confirmed 
in an in vivo murine xenograft model.  
 
To date, most studies investigating the on-target off-tumor effects of CAR T cell therapy make the use 
of artificial modeling for “healthy cells” using tumor cell lines which express or are transduced to 
express the target antigen in low levels.15,16,35 Although valuable in several aspects, such an approach 
is not ideal for evaluating the off-tumor effects of CAR T cells, since several other differences 
between tumor and healthy cells, especially the differences in susceptibility to cytolysis, are neglected. 
Therefore in our approach we always compared primary tumor cells with primary healthy cells, whose 
relative low proliferation rate may render them more susceptible to cytotoxicity. Moreover, in order to 
reduce variability and to simulate the in vivo clinical setting as good as possible, we executed all our in 
vitro testing of tumor cells and the healthy cells side by side, in the same compartment (BM) and at the 
same time. As it is suggested that results from in vivo models are more relevant for the potential 
toxicity of CAR T cell treatment,34 we also used primary human hematopoietic progenitor cells in our 
in vivo assays. In this model, CD34+ hematopoietic progenitor cells, which were inoculated in a 
humanized xenografted environment13,29,36 were detectable up to three weeks in all treatment groups. 
This three-week evaluation period was sufficient since in the same time frame we also detected the 
highest level of anti-MM reactivity. Neither the high affinity CAR T cells nor the optimized affinity 
CAR T cells disturbed the FLI signal from the inoculated CD34 progenitor cells. However, further 
analyses revealed that the maintenance of the CD38+ progenitor compartment was achieved only in 
mice treated with the low affinity CARA4, confirming the low reactivity of our lead candidate towards 
healthy CD38+ cells.  
Finally, while we have been able to optimize the antigen recognition affinity of CARs, we think that 
these CARs need further evaluation with respect to their signaling requirements as we have tested only 
CARs with a 4-1BB co-stimulatory domain. It has recently been shown that that differences in the 
CAR configuration, either harboring CD28 or 4-1BB co-stimulatory domains, has a large effect on the 
killing capacity or persistence of CAR T cells.25,37–40 In order to retain a certain pressure on tumor 




proliferation and cytokine production.25,37,41 Accordingly, patient relapses seen in CAR-trials can be 
caused due to the poor longevity and persistence of CAR T cells. The differentiation status of the CAR 
T cells (central memory, effector memory or effectors) can somehow predict the in vivo longevity of 
the CAR T cells. Interestingly, in contrast to previous studies,14–16,34 where no difference in 
immunophenotype was observed when lowering the affinity of CARs, we found the maintenance of 
CD38+ CAR T cells when using the lower affinity CARs (Supplemental Fig. S3). Furthermore, we 
observed an apparent higher percentage of naïve and central memory cells in lower affinity CD38-
CAR T cells compared to the original CAR028 T cells at the end of production stage, after which the 
CART cells are generally injected in vivo. Nonetheless, all cells eventually converted to the effector 
memory phenotype after prolonged in vitro culture, suggesting that the use of other co-stimulatory 
domains could reveal more optimal designs for low affinity CARs. 
 
In conclusion, our data support the feasibility of the light chain exchange method as a new approach to 
generate a large panel of scFvs with a wide range of affinities for a TAA epitope. We, here, propose a 
stepwise rational in vitro and in vivo assessment and scoring of lower affinity CAR T cells in order to 
identify candidates with a strong tumoricidal function and minimal off-tumor toxicity. In addition to 
scFv affinity, future studies should include other aspects of the CAR design such as the costimulatory 






Acknowledgements: The authors thank Michel Sadelain (MSKCC) for providing the retroviral 
construct SFG with 4-1BB-CD3ζ–LNGFR transgene. The RAG2-/-γc-/- mice used in this study were 
originally obtained from the Amsterdam Medical Center (AMC, Amsterdam, The Netherlands). We 
also thank Patrick Celie from the NKI Protein Facility for cloning, expression and purification of 
recombinant CD38 protein and to Genmab Utrecht for technical and infrastructure assistance in the 
production and testing of new antibodies with the light chain exchange technology. This work is in 
part executed by the financial support of ‘Fonds Stimulans’ the Netherlands (E.D. and T.M) and the 
European Commission (Marie Curie Individual Fellowship to M.T.) 
Conflict of interest disclosure: T.M., H.M.L. and N.W.C.J.D. received project grant support from 
Genmab, Janssen and Celgene.  
Author contribution: Conceptualization, E.D., M.T., R.W.J.G., H.M.L. and T.M.; Investigation, 
E.D., M.T., R.P., R.J.K.; Formal analysis, E.D. M.T. and T.M.; Resources, A.C.M.M., R.W.J.G., H.Y. 
and J.B.; Writing – Original Draft, E.D., M.T. and T.M.; Writing – Review & Editing, E.D., M.T., 
R.P., A.C.M.M., R.W.J.G., S.Z., N.W.C.J.D., H.M.L. and T.M.; Funding Acquisition, H.M.L. and 







1. Porter, DL, Levine, BL, Kalos, M, Bagg, A and June, CH (2011). Chimeric antigen receptor-
modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365: 725–733. 
2. Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR, et al. (2013). 
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. N. Engl. J. Med. 
368: 1509–1518. 
3. Maude, SL, Frey, N, Shaw, P a., Aplenc, R, Barrett, DM, Bunin, NJ, et al. (2014). Chimeric 
Antigen Receptor T Cells for Sustained Remissions in Leukemia. N. Engl. J. Med. 371: 1507–
1517. 
4. Brentjens, RJ, Rivière, I, Park, JH, Davila, ML, Wang, X, Stefanski, J, et al. (2011). Safety and 
persistence of adoptively transferred autologous CD19-targeted T cells in patients with 
relapsed or chemotherapy refractory B-cell leukemias. Blood 118: 4817–4828. 
5. Kochenderfer, JN, Dudley, ME, Feldman, S a, Wilson, WH, Spaner, DE, Maric, I, et al. (2012). 
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a 
clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709–
2720. 
6. Cheever, MA, Allison, JP, Ferris, AS, Finn, OJ, Hastings, BM, Hecht, TT, et al. (2009). The 
prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of 
translational research. Clin. Cancer Res. 15: 5323–5337. 
7. Sadelain, M, Brentjens, R and Rivière, I (2013). The basic principles of chimeric antigen 
receptor design. Cancer Discov. 3: 388–398. 
8. Lamers, CHJ, Sleijfer, S, Vulto, AG, Kruit, WHJ, Kliffen, M, Debets, R, et al. (2006). 
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically 
retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24: 904–912. 
9. Parkhurst, MR, Yang, JC, Langan, RC, Dudley, ME, Nathan, D-AN, Feldman, SA, et al. 
(2011). T cells targeting carcinoembryonic antigen can mediate regression of metastatic 
colorectal cancer but induce severe transient colitis. Mol. Ther. 19: 620–626. 
10. Davila, ML, Riviere, I, Wang, X, Bartido, S, Park, J, Curran, K, et al. (2014). Efficacy and 
toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. 
Sci. Transl. Med. 6: 224–225. 
11. Lee, DW, Kochenderfer, JN, Stetler-Stevenson, M, Cui, YK, Delbrook, C, Feldman, SA, et al. 
(2014). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia 
in children and young adults: a phase 1 dose-escalation trial. Lancet 385: 517–528. 
12. Morgan, R a, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM and Rosenberg, S a (2010). 
Case report of a serious adverse event following the administration of T cells transduced with a 




13. Drent, E, Groen, RWJ, Noort, WA, Themeli, M, Lammerts van Bueren, JJ, Parren, PWHI, et 
al. (2016). Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the 
treatment of multiple myeloma. Haematologica 101: 616–625. 
14. Hudecek, M, Lupo-Stanghellini, M-T, Kosasih, PL, Sommermeyer, D, Jensen, MC, Rader, C, 
et al. (2013). Receptor affinity and extracellular domain modifications affect tumor recognition 
by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19: 3153–3164. 
15. Caruso, HG, Hurton, L V., Najjar, A, Rushworth, D, Ang, S, Olivares, S, et al. (2015). Tuning 
Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining 
Potent Antitumor Activity. Cancer Res. 75: 3505–3518. 
16. Liu, X, Jiang, S, Fang, C, Yang, S, Olalere, D, Pequignot, EC, et al. (2015). Affinity-Tuned 
ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index 
against Tumors in Mice. Cancer Res. 75: 3596–3607. 
17. Carter, P, Presta, L, Gorman, CM, Ridgway, JB, Henner, D, Wong, WL, et al. (1992). 
Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. 
U. S. A. 89: 4285–4289. 
18. Chmielewski, M, Hombach, A, Heuser, C, Adams, GP and Abken, H (2004). T cell activation 
by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain 
above threshold does not increase T cell activation against antigen-positive target cells but 
decreases selectivity. J. Immunol. 173: 7647–7653. 
19. Zhou, Y, Drummond, DC, Zou, H, Hayes, ME, Adams, GP, Kirpotin, DB, et al. (2007). Impact 
of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal 
Growth Factor Receptor-expressing Tumor Cells. J. Mol. Biol. 371: 934–947. 
20. Jayaram, N, Bhowmick, P and Martin, ACR (2012). Germline VH/VL pairing in antibodies. 
Protein Eng. Des. Sel. 25: 523–529. 
21. Yoshinaga, K, Matsumoto, M, Torikai, M, Sugyo, K, Kuroki, S, Nogami, K, et al. (2008). Ig L-
chain Shuffling for Affinity Maturation of Phage Library-derived Human Anti-human MCP-1 
Antibody Blocking its Chemotactic Activity. J. Biochem. 143: 593–601. 
22. Senn, BM, López-Macías, C, Kalinke, U, Lamarre, A, Isibasi, A, Zinkernagel, RM, et al. 
(2003). Combinatorial immunoglobulin light chain variability creates sufficient B cell diversity 
to mount protective antibody responses against pathogen infections. Eur. J. Immunol. 33: 950–
961. 
23. Wardemann, H, Hammersen, J and Nussenzweig, MC (2004). Human autoantibody silencing 
by immunoglobulin light chains. J. Exp. Med. 200: 191–199. 
24. Vink, T, Oudshoorn-Dickmann, M, Roza, M, Reitsma, J-J and de Jong, RN (2014). A simple, 
robust and highly efficient transient expression system for producing antibodies. Methods 65: 
5–10. 




Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and 
Persistence of CAR T Cells. Cancer Cell 28: 415–428. 
26. Kim, JH, Lee, S-R, Li, L-H, Park, H-J, Park, J-H, Lee, KY, et al. (2011). High Cleavage 
Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, 
Zebrafish and Mice. In: Thiel, V (ed.). PLoS One 6: e18556. 
27. Luna-Vargas, MPA, Christodoulou, E, Alfieri, A, van Dijk, WJ, Stadnik, M, Hibbert, RG, et al. 
(2011). Enabling high-throughput ligation-independent cloning and protein expression for the 
family of ubiquitin specific proteases. J. Struct. Biol. 175: 113–119. 
28. Sari, D, Gupta, K, Thimiri Govinda Raj, DB, Aubert, A, Drncová, P, Garzoni, F, et al. (2016). 
The MultiBac Baculovirus/Insect Cell Expression Vector System for Producing Complex 
Protein Biologics. Adv. Exp. Med. Biol. 896: 199–215. 
29. Groen, RWJ, Noort, W a, Raymakers, RA, Prins, H-JJ, Aalders, L, Hofhuis, FM, et al. (2012). 
Reconstructing the human hematopoietic niche in immunodeficient mice: Opportunities for 
studying primary multiple myeloma. Blood 120: 9–16. 
30. Bostrom, J, Yu, S-F, Kan, D, Appleton, BA, Lee, C V., Billeci, K, et al. (2009). Variants of the 
Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site. Science 
(80-. ). 323: 1610–1614. 
31. Lamdan, H, Gavilondo, J V, Muñoz, Y, Pupo, A, Huerta, V, Musacchio, A, et al. (2013). 
Affinity maturation and fine functional mapping of an antibody fragment against a novel 
neutralizing epitope on human vascular endothelial growth factor. Mol. BioSyst. Mol. BioSyst 
9: 2097–2106. 
32. Raposo, B, Dobritzsch, D, Ge, C, Ekman, D, Xu, B, Lindh, I, et al. (2014). Epitope-specific 
antibody response is controlled by immunoglobulin V(H) polymorphisms. J. Exp. Med. 211: 
405–411. 
33. Ramos, CA, Savoldo, B and Dotti, G (2014). CD19-CAR trials. Cancer J. 20: 112–118. 
34. Johnson, LA, Scholler, J, Ohkuri, T, Kosaka, A, Patel, PR, McGettigan, SE, et al. (2015). 
Rational development and characterization of humanized anti-EGFR variant III chimeric 
antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7: 275ra22. 
35. Morsut, L, Roybal, KT, Xiong, X, Gordley, RM, Coyle, SM, Thomson, M, et al. (2016). 
Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch 
Receptors. Cell 164: 780–791. 
36. de Haart, SJ, van de Donk, NWCJ, Minnema, MC, Huang, JH, Aarts-Riemens, T, Bovenschen, 
N, et al. (2013). Accessory cells of the microenvironment protect multiple myeloma from T-
cell cytotoxicity through cell adhesion-mediated immune resistance. Clin. Cancer Res. 19: 
5591–5601. 
37. Abken, H (2016). Costimulation Engages the Gear in Driving CARs. Immunity 44: 214–216. 




Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival 
of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17: 1453–1464. 
39. Kowolik, CM, Topp, MS, Gonzalez, S, Pfeiffer, T, Olivares, S, Gonzalez, N, et al. (2006). 
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in 
vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66: 
10995–11004. 
40. Cherkassky, L, Morello, A, Villena-Vargas, J, Feng, Y, Dimitrov, DS, Jones, DR, et al. (2016). 
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated 
inhibition. J. Clin. Invest. 126: 3130–3144. 
41. van der Stegen, SJC, Hamieh, M and Sadelain, M (2015). The pharmacology of second-









Figure 1 Selection of low affinity CD38 antibodies. (A) Schematic cartoon of light chain exchange 
method and overview of antibody generation and selection process. (B) Representative graphs of 
binding assays performed with CHO cells transfected with CD38 (CHO-CD38) or wildtype (WT). 
His-CD38 are beads coated with recombinant CD38 and detected with IgG or Fab fragments with 
fluorchrome beads. Rows indicate wildtype (WT 028) antibody 028 and class A, B and C, as defined 
by A= positive binding in all assays, B= positive in the cell binding and IgG, C= only positive binding 
on CHO-CD38. (C) Quantified EC50 values (mg/ml) of different binding assays. (D) Molecule 
association and dissociation curves. Interferometric profile shifts are measured and its magnitude is 
plotted as a function of time. (E) Interferometric profiles of the antibodies are quantified into KD 
values (M), on and off-rates (Kon (1/Ms) and Koff (1/s)). N=2 +/- SD.  
 
Figure 2 Lytic capacity of different affinity CD38-CAR T cells. Lysis of cell line UM9 by different 
affinity CD38-CAR T cells when co-incubated with luciferase-transduced MM cell line UM9 for a 16 
hours, cytotoxicity was measured with BLI, n=2. Graphs are divided in three affinity subcategories. 
Class A CARs are derived from class A antibodies, with the highest affinity, to class C with the lowest 
affinity. CARs with the 028 variable heavy chain (VH) are numbered 1-4 in each class and CARs with 
024 VH 5-8. 
 
Figure 3 Phenotypic profiles of lower affinity CD38-CAR T cells. (A) 24 hours after co-incubation 
with CD38+ target cell line UM9 or CD38- target U266, E:T ratio 1:1, cytokine secretion by mock or 
CD38-CAR028, A1, A4, B1 or B3 T cells was measured with a flow cytometry-based assay in the cell 
free supernatants. Graph shows the secretion of IFN-γ, TNF and IL-2. n=2, mean +/- SEM, * indicates 
p value <0.05 and ** <0.01 using one-way analysis of variance and subsequent multiple comparison. 
(B) CD38-CAR T cells were stimulated with MM target UM9 E:T ratio 1:3 one week after transduced 
and followed weekly. Cells were counted and % of CAR+ cells were determined by flow cytometry. 




indicate CD38-CAR028, () CARA1, () CARA4, () CARB1, () CARB3. N=2 mean +/- SEM, 
ns=not significant (C) Phenotypic profile of each CD38-CAR T cell type was determined before (week 
0) and after (week 1) expansion with markers CD45RA and CD62L. Percentage of total of cells is 
depicted naive (CD45RA+/CD62L+) central memory (CM) (CD45RA-/CD62L+), effector memory 
(EM) (CD45RA-/CD62L-). N=2 mean +/- SEM, ns=not significant. Statistical analysis was done using 
one-way analysis of variance and subsequent multiple comparison. 
 
Figure 4 Lytic capacity of lower affinity CD38-CAR T cells towards Multiple Myeloma bone 
marrow. Bone marrow (BM-MNCs) samples of four MM patients with 20-40% MM cells were co-
incubated, mock or CD38-CAR028, A1, A4, B1 or B3 T cells for 16 h. The graphs depict the resulting 
lysis of (A) CD138+/CD38+ cells (MM) (B) CD38+ MNCs (non-MM) and (C) total MNCs in E:T 
(E:BM-MNC) ratio 1:1. Representative figure of other ratios in supplemental Fig. S5. () indicate 
mock and open squares () indicate CD38-CAR028, () CARA1, () CARA4, () CARB1, () 
CARB3. The % lysis in these flow cytometry assays was calculated as described in the methods 
section. N=4, median +/- range, * indicates p value <0.05 and ** <0.01 using Kruskal-Wallis analysis 
of variance and subsequent Mann-Whitney comparison. (D) Flow cytometry dot plots depicting MM-
BM with CD138+/CD38++ cells (MM), and CD138-/CD38+ healthy cells. The CD38 threshold for lysis 
is indicated with 2 horizontal bars on voltage 103 (threshold for high affinity CD38-CAR028) and 104 
for some of the lower affinity CD38-CARs.  
 
Figure 5 CARA4 is the best candidate for a lower affinity CAR. Peripheral blood mononuclear 
cells (PBMCs) of a healthy donor were co-incubated with mock, high affinity CD38-CAR028 or low 
affinity CD38-CARA4 T cells for 16 h. The graphs depict the resulting lysis of CD3+ (T cells), CD56+ 
(NK cells) or CD19+ (B cells), their total or CD38+ fraction. Circles () indicate mock and open 
squares () indicate CD38-CAR028, triangle () CARA1 and diamond () CARA4. The % lysis in 





Figure 6 High and low affinity CD38-CAR T cells are similarly effective in vivo. Mice were i.v. 
injected with 10x106 cells of tumor cell line UM9 and treated one week after with i.v. injections of 5 x 
106 mock, high affinity CD38-CAR028 or low affinity CD38-CARA4 T cells. (A) Bioluminescence 
images (BLI) are shown per group of each week. (B) Analysis of tumor load in mice by quantification 
of BLI measurements. Each group contained four mice, each harboring 4 scaffolds. Closed circles () 
indicate mock and open squares (□) indicate CD38-CAR028 and () CD38-CARA4. N=4, Results 
are median tumor load (cpm/cm2) of 4 mice +/- range, * indicates p value <0.05, ** <0.01 and *** 
<0.001 using Kruskal-Wallis analysis of variance.   
 
Figure 7 High affinity CD38-CAR T cells affect CD34 hematopoietic progenitor cells. (A) Mice 
were intrascaffold injected with 1 x 106 fluorescently (FarRed) labeled CD34+ and treated one week 
after with i.v. injections of 5 x 106 mock, high affinity CD38-CAR028 or low affinity CD38-CARA4 
T cells. (A) Fluorescence images (FLI) are shown per group at week 1 and 3. (B) Percentages of 
CD34+/- and CD38+/- cells in the total population of FarRed+ cells, that were present in the scaffold in 
post-mortem tissue samples analyzed by flow cytometry. Results % CD34+/- and CD38+/- of four mice 
per group, two scaffold per mouse +/- range, * indicates p value <0.05, using Mann-Whitney test on 
CD38+ percentages. (C) Total number of manually counted cells were adjusted using the percentage of 
FarRed+ cells as measured by flow cytometry and the percentage of CD34+/- and CD38+/- in B. N=4 
mice per group, median +/- range. 
 







